DIAMEDICA THERAPEUTICS INC's ticker is DMAC and the CUSIP is 25253X207. A total of 29 filers reported holding DIAMEDICA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $66,479 | -31.6% | 24,000 | -29.9% | 0.00% | – |
| Q4 2023 | $97,221 | +8.9% | 34,233 | -1.1% | 0.00% | – |
| Q3 2023 | $89,311 | -42.4% | 34,617 | -3.6% | 0.00% | – |
| Q2 2023 | $155,062 | +181.0% | 35,894 | -0.5% | 0.00% | – |
| Q1 2023 | $55,175 | -3.2% | 36,062 | 0.0% | 0.00% | – |
| Q4 2022 | $56,982 | +26.6% | 36,062 | -0.5% | 0.00% | – |
| Q3 2022 | $45,000 | -38.4% | 36,248 | 0.0% | 0.00% | – |
| Q2 2022 | $73,000 | -19.8% | 36,248 | -0.5% | 0.00% | – |
| Q1 2022 | $91,000 | -51.1% | 36,412 | -27.0% | 0.00% | – |
| Q4 2021 | $186,000 | -7.0% | 49,884 | 0.0% | 0.00% | – |
| Q3 2021 | $200,000 | +17.6% | 49,884 | +30.3% | 0.00% | – |
| Q2 2021 | $170,000 | -54.2% | 38,284 | -5.6% | 0.00% | – |
| Q1 2021 | $371,000 | -14.7% | 40,576 | -5.4% | 0.00% | – |
| Q4 2020 | $435,000 | +663.2% | 42,905 | +218.5% | 0.00% | – |
| Q3 2020 | $57,000 | -38.7% | 13,472 | 0.0% | 0.00% | – |
| Q2 2020 | $93,000 | – | 13,472 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 325,000 | $1,404,000 | 2.87% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 198,730 | $858,514 | 0.97% |
| Bleichroeder LP | 294,117 | $1,270,585 | 0.26% |
| EAM Investors, LLC | 270,419 | $1,168,210 | 0.22% |
| COOPERMAN LEON G | 875,993 | $3,784,290 | 0.20% |
| CATALYST FINANCIAL PARTNERS LLC | 36,267 | $156,673 | 0.06% |
| Legend Financial Advisors, Inc. | 1,000 | $4,320 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 124,744 | $538,894 | 0.00% |
| Tower Research Capital LLC (TRC) | 6,240 | $26,957 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 4,824 | $20,840 | 0.00% |